Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-120-9 | CAS number: 2634-33-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
Materials and methods
- Objective of study:
- absorption
- Principles of method if other than guideline:
- Method: conducted in accordance with scientifically accepted method
- GLP compliance:
- yes
Test material
- Reference substance name:
- 1,2-benzisothiazol-3(2H)-one
- EC Number:
- 220-120-9
- EC Name:
- 1,2-benzisothiazol-3(2H)-one
- Cas Number:
- 2634-33-5
- Molecular formula:
- C7H5NOS
- IUPAC Name:
- 1,2-benzisothiazol-3(2H)-one
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- Test material
Nipacide BIT
Radiolabelled BIT
Lot/Batch number
Radiolabelled BIT: CFQ9246
Non-radiolabelled BIT: D909
Purity
Radiolabelled BIT: >98%
Non-radiolabelled BIT: 96.8% - Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
Administration / exposure
- Route of administration:
- other: oral (gavage) and dermal
- Vehicle:
- other: Proplyene glycol : Glycerol : Distilled water (45 : 30 : 25)
- Details on exposure:
- Oral dose (Group 1): 4, 8*, 24*, 48 and 72* hours (tissue distribution, *WBA also)
Dermal dose (Group 2): 4, 8*, 24*, 48 and 72* hours (tissue distribution, *WBA also) - Duration and frequency of treatment / exposure:
- 72 hour(s)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Males: oral and dermal at dose level of 10 mg/kg body weight
- No. of animals per sex per dose / concentration:
- Males: 8 per group
- Control animals:
- no
Results and discussion
Main ADME resultsopen allclose all
- Type:
- excretion
- Results:
- 96.6% of the dose absorbed following topical application and 99.5% of the dose absorbed following oral administration was excreted in 72 hours
- Type:
- absorption
- Results:
- 96.6% of dose was absorbed orally
- Type:
- distribution
- Results:
- Less than 0.05% of the dose remained in any tissue at 48 hours after oral administration and topical application
Metabolite characterisation studies
- Metabolites identified:
- not measured
Applicant's summary and conclusion
- Conclusions:
- Materials and methods
The absorption, distribution and excretion of radiolabelled material was determined at 4, 8, 24, 48 and 72 hours following a single oral administration or a single topical application of [14C]-Nipacide BIT (approximately 10 mg/kg; 5 MBq/kg). Any unabsorbed material was removed from the site by washing with 1% Tween 80 following the final collection.
Animals were sacrificed for quantitative whole body autoradiography at 8, 24 and 72 hours following both oral administration and topical application.
Results and discussion
The overall recoveries of radioactive material were 100 ± 2.0% for orally dosed animals and 106 ± 1.6% for topically dosed animals.
At 8 hours after a topical application, 3.2% of the radiochemical dose was absorbed and 23.9% remained in the treated skin and was, therefore, available for absorption.
At 72 hours after a topical application, 41.6% of the radiochemical dose was absorbed and 47.6% remained in the treated skin and was, therefore, available for absorption.
Radioactive material was rapidly and extensively absorbed through the skin and from the gastrointestinal tract. At 8 hours after an oral administration, 96.6% of the radiochemical dose was detected in samples other than the gastrointestinal tract. At 72 hours after a topical application, 41.6% of the radiochemical dose was absorbed and 47.6% remained in the treated skin and was, therefore, available for absorption.
The primary route of excretion was in the urine, with 96.6% of the activity absorbed following topical application and 99.5% of the radiochemical dose following oral administration, being excreted by this route in 72 hours.
Very little material was detected in the faeces, indicating that the majority of the radioactive material is absorbed following oral administration and that biliary excretion is unlikely to occur to any great extent (low levels of radioactive material were detected in the faeces and gastrointestinal tract (less than 0.5% of the radiochemical dose combined) following topical application).
The test material does not appear to be broken down to volatile components or excreted in the expired carbon dioxide, as indicated by high overall recoveries and low trap levels (less than 0.05% of the radiochemical dose) of radioactivity in trapping solutions.
Tissue disposition does not appear to occur. Less than 0.05% of the radiochemical dose remained in any tissue at 48 hours after oral administration and topical application, with the exception of the carcass and untreated skin following topical application which, combined, contained less than 1.5% of the radiochemical dose.
Conclusion
[14C]-Nipacide BIT is rapidly and extensively absorbed from the gastrointestinal tract and through the skin, and is then rapidly excreted, primarily in the urine, with little or no tissue disposition. Low levels of radioactivity were detected in the faeces, indicating that the majority of the radioactivity is absorbed following oral administration and that biliary excretion is unlikely to occur (low gastrointestinal tract and faeces levels following dermal application). The test material is not broken down into volatile components or expired as carbon dioxide. - Executive summary:
A study was conducted to study the absorption, distribution and excretion profile of the substance in Sprague-Dawley rats. The toxicokinetic profile was determined at 4, 8, 24, 48 and 72 hours following a single oral administration or a single topical application of the radiolabelled test substance at approximately 10 mg/kg bw (5 MBq/kg). Any unabsorbed material was removed from the site by washing with 1% Tween 80 following the final collection. Animals were sacrificed for quantitative whole body autoradiography at 8, 24 and 72 hours following both oral administration and topical application. The overall recoveries of radioactive material were 100 ± 2.0% for orally dosed animals and 106 ± 1.6% for topically dosed animals. At 8 hours after a topical application, 3.2% of the radiochemical dose was absorbed and 23.9% remained in the treated skin and was, therefore, available for absorption. At 72 hours after a topical application, 41.6% of the radiochemical dose was absorbed and 47.6% remained in the treated skin and was, therefore, available for absorption. Radioactive material was rapidly and extensively absorbed through the skin and from the gastrointestinal tract. At 8 hours after an oral administration, 96.6% of the radiochemical dose was detected in samples other than the gastrointestinal tract. At 72 hours after a topical application, 41.6% of the radiochemical dose was absorbed and 47.6% remained in the treated skin and was, therefore, available for absorption. The primary route of excretion was in the urine, with 96.6% of the activity absorbed following topical application and 99.5% of the radiochemical dose following oral administration, being excreted by this route in 72 hours. Very little material was detected in the faeces, indicating that the majority of the radioactive material is absorbed following oral administration and that biliary excretion is unlikely to occur to any great extent (low levels of radioactive material were detected in the faeces and gastrointestinal tract (less than 0.5% of the radiochemical dose combined) following topical application). The test substance does not appear to be broken down to volatile components or excreted in the expired carbon dioxide, as indicated by high overall recoveries and low trap levels (less than 0.05% of the radiochemical dose) of radioactivity in trapping solutions. Tissue disposition does not appear to occur. Less than 0.05% of the radiochemical dose remained in any tissue at 48 hours after oral administration and topical application, with the exception of the carcass and untreated skin following topical application which, combined, contained less than 1.5% of the radiochemical dose. Based on the study results, it can concluded that the substance is rapidly and extensively absorbed from the gastrointestinal tract and through the skin, and is then rapidly excreted, primarily in the urine, with little or no tissue disposition. Low levels of radioactivity were detected in the faeces, indicating that the majority of the radioactivity is absorbed following oral administration and that biliary excretion is unlikely to occur (low gastrointestinal tract and faeces levels following dermal application). The test substance is not broken down into volatile components or expired as carbon dioxide (O'Connor, 1999).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.